You can read the IBTA e-News September 2017 edition in full online here.
Some of the highlights from this month's include:
- Data presented as a late-breaking abstract at this month’s American Society for Radiation Oncology’s 2017 Annual Meeting in San Diego, USA, has shown that addition of Optune TTFields therapy improves five-year survival in newly-diagnosed glioblastoma (13% vs 5%).
- A study has found that a significant proportion of children and young adults who develop a solitary meningioma or schwannoma have an underlying genetic predisposition, meaning that these conditions warrant referral for genetic testing.
- A study published in Nature Neuroscience has identified the three-dimensional DNA looping processes that drive glioma tumour growth, suggesting a possible target for future therapies.
- According to a study published in The Journal of Experimental Medicine, the stem cell-targeting properties of the Zika virus could be harnessed to develop new brain tumour therapies.
- A multinational research collaboration called the WINDOW Consortium, which will establish an international and multi-disciplinary research network, has been awarded a grant of £1.5 million (€1.75 million / US$2.0 million) by The Brain Tumour Charity (UK) for glioblastoma research.
- The Australian government has announced that paediatric brain tumour patients will be able to enrol on the AIM BRAIN project from 31st October 2017. This coincides with the news that the four-year clinical study has secured funding from the federal cancer research budget.
- A study analysing data from the US National Cancer Database has found that glioblastoma patients who are seen in ‘high volume’ hospitals were significantly more likely to receive treatment, and have a better survival, than those attending low volume hospitals.
- The Brain Tumour Society Singapore is campaigning for a national brain tumour registry and are conducting a quality-of-life survey open to all brain tumour patients and caregivers in Singapore.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.